STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLPT
  4. [Form 4] ClearPoint Neuro, Inc. Insider Trading Activity

ClearPoint Neuro (CLPT) CEO exercises options and sells 20,000 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. director and CEO Joseph Burnett reported an option exercise and related share sale in Common Stock. He exercised stock options to acquire 20,000 shares at $2.50 per share and sold 20,000 shares in an open-market transaction at a weighted average price of $19.38 per share.

Following these transactions, he holds 116,842 shares directly and 191,388 shares indirectly through the Joseph M. Burnett Trust. The filing notes the exercise and sale were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025.

Positive

  • None.

Negative

  • None.
Insider BURNETT JOSEPH
Role CEO and President
Sold 20,000 shs ($388K)
Type Security Shares Price Value
Exercise Stock Options (right to buy) 20,000 $0.00 --
Exercise Common Stock 20,000 $2.50 $50K
Sale Common Stock 20,000 $19.38 $388K
holding Common Stock -- -- --
Holdings After Transaction: Stock Options (right to buy) — 250,000 shares (Direct, null); Common Stock — 136,842 shares (Direct, null); Common Stock — 191,388 shares (Indirect, See Footnote)
Footnotes (1)
  1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1. Represents a weighted average sales price per share. The shares were sold at prices ranging from $19.15 to $19.54. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust. The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a quarterly basis over the 2-year period immediately following the first anniversary of the grant date. The grant date is November 7, 2017.
Shares sold 20,000 shares Common Stock open-market sale on June 29, 2026
Sale price $19.38 per share Weighted average sale price; range $19.15–$19.54
Options exercised 20,000 shares Common Stock acquired via stock option exercise
Exercise price $2.50 per share Stock options (right to buy) conversion price
Direct holdings after 116,842 shares Common Stock held directly following transactions
Indirect holdings after 191,388 shares Common Stock held via Joseph M. Burnett Trust
Net share change -20,000 shares Net of all buy/sell transactions in this Form 4
10b5-1 plan adoption date June 11, 2025 Date written trading plan was adopted
Rule 10b5-1 regulatory
"made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Options (right to buy) financial
"security_title": "Stock Options (right to buy)""
weighted average sales price financial
"Represents a weighted average sales price per share."
vest financial
"The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date;"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BURNETT JOSEPH
(Last)(First)(Middle)
C/O CLEARPOINT NEURO, INC.
120 S. SIERRA AVE., SUITE 100
(Street)
SOLANA BEACH CALIFORNIA 92075
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO and President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/29/2026M(1)20,000A$2.5136,842D
Common Stock06/29/2026S(1)20,000D$19.38(2)116,842D
Common Stock191,388ISee Footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (right to buy)$2.506/29/2026M(1)20,000 (4)11/07/2027Common Stock20,000$0250,000D
Explanation of Responses:
1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1.
2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $19.15 to $19.54. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.
4. The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a quarterly basis over the 2-year period immediately following the first anniversary of the grant date. The grant date is November 7, 2017.
/s/ Danilo D'Alessandro, by Power of Attorney for Joseph M. Burnett07/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ClearPoint Neuro (CLPT) CEO Joseph Burnett report?

Joseph Burnett reported exercising options for 20,000 ClearPoint Neuro shares at $2.50 and selling 20,000 shares at a weighted average of $19.38. These transactions were recorded as an option exercise and an open-market sale on June 29, 2026.

How many ClearPoint Neuro (CLPT) shares does Joseph Burnett hold after this Form 4?

After the reported transactions, Joseph Burnett holds 116,842 ClearPoint Neuro shares directly and 191,388 shares indirectly through the Joseph M. Burnett Trust. These holdings reflect his position as of the June 29, 2026 transactions disclosed.

Was the ClearPoint Neuro (CLPT) CEO’s stock sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the options exercised and shares sold were made under a written Rule 10b5-1 trading plan adopted on June 11, 2025. Such plans schedule trades in advance, making them more routine and less about short-term market timing.

What prices were involved in Joseph Burnett’s ClearPoint Neuro (CLPT) transactions?

The option exercise price was $2.50 per share for 20,000 shares. The 20,000 shares sold had a weighted average sales price of $19.38, with individual sale prices ranging from $19.15 to $19.54, as disclosed in the filing’s footnotes.

How are Joseph Burnett’s indirect ClearPoint Neuro (CLPT) holdings structured?

The Form 4 explains that 191,388 shares are held by the Joseph M. Burnett Trust dated October 20, 2022. Joseph Burnett is trustee of this trust, so these shares are reported as indirectly owned through that trust structure in the filing.